These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8120550)

  • 1. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
    White L; McCowage G; Kannourakis G; Nayanar V; Colnan L; Kellie S; Shaw P; Seshadri R; Lockwood L; Tiedemann K
    J Clin Oncol; 1994 Mar; 12(3):522-31. PubMed ID: 8120550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
    Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
    Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors.
    Ziegler DS; Cohn RJ; McCowage G; Alvaro F; Oswald C; Mrongovius R; White L;
    Neuro Oncol; 2006 Jan; 8(1):53-9. PubMed ID: 16443948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
    McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
    Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group study.
    McCowage GB; Mrongovius R; Alvaro F; Cohn RJ; Ziegler DS; Oswald C; White L;
    Pediatr Blood Cancer; 2011 Dec; 57(6):958-64. PubMed ID: 21793175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study.
    Mantadakis E; Herrera L; Leavey PJ; Bash RO; Winick NJ; Kamen BA
    J Clin Oncol; 2000 Jul; 18(13):2576-81. PubMed ID: 10893289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Marina NM; Rodman J; Shema SJ; Bowman LC; Douglass E; Furman W; Santana VM; Hudson M; Wilimas J; Meyer W
    J Clin Oncol; 1993 Mar; 11(3):554-60. PubMed ID: 8445431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
    Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
    J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
    Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
    J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
    J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation.
    Neidhart JA; Kohler W; Stidley C; Mangalik A; Plauche A; Anderson T; Quenzer RW; Rinehart JJ
    J Clin Oncol; 1990 Oct; 8(10):1728-38. PubMed ID: 2213108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Wexler LH; DeLaney TF; Tsokos M; Avila N; Steinberg SM; Weaver-McClure L; Jacobson J; Jarosinski P; Hijazi YM; Balis FM; Horowitz ME
    Cancer; 1996 Aug; 78(4):901-11. PubMed ID: 8756388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
    Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
    Finlay JL; Goldman S; Wong MC; Cairo M; Garvin J; August C; Cohen BH; Stanley P; Zimmerman RA; Bostrom B; Geyer JR; Harris RE; Sanders J; Yates AJ; Boyett JM; Packer RJ
    J Clin Oncol; 1996 Sep; 14(9):2495-503. PubMed ID: 8823328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors.
    Heideman RL; Kovnar EH; Kellie SJ; Douglass EC; Gajjar AJ; Walter AW; Langston JA; Jenkins JJ; Li Y; Greenwald C
    J Clin Oncol; 1995 Sep; 13(9):2247-54. PubMed ID: 7666082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.